|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Physio-Control Field Correction to LIFEPAK(R) 20/20e Defibrillator/ Monitors
7/6/2010 1:17:27 PM
MINNEAPOLIS--(BUSINESS WIRE)--Physio-Control, Inc., a wholly owned subsidiary of Medtronic, Inc., (NYSE: MDT), announced the company’s recent initiation of a field correction on certain LIFEPAK 20/20e defibrillator/monitors manufactured prior to January 9, 2009. Analysis conducted by Physio-Control verified a possible battery (DC) power malfunction on the affected devices. In the malfunction scenario, a loss of battery power may occur while the unit is in operation. The LIFEPAK 20/20e defibrillator/monitor was designed with a dual power supply system. The primary source of power is wall (AC) power, which remains available in the event of the loss of battery power. If a malfunction of battery power occurs, customers can plug the device into wall (AC) power to relieve the reliability issue. A loss of DC power during patient use is highly unlikely, but if it occurs and AC power is not readily available, it could delay the delivery of defibrillation therapy, which could potentially result in serious injury or death. While there have been reports of failures during patient use, over the eight year product life, there has been one unconfirmed adverse patient event.
|
|
|
|
|
|
|
|
|
|
|